INTRODUCTION
Immunotherapy is a promising approach for the treatment of established neoplastic disease. Many tumors share the expression of tumor-specific antigens not found in healthy cells, raising the possibility of invoking immune responses that selectively target diseased cells.
Ewing Sarcoma, and the historically named Primitive Neuroectodermal Tumor (pPNET), Biphenotypic Sarcoma and Askin's tumor, all share recurrent translocations that involve fusion of the EWS gene (22q-12) to genes encoding ETS transcription factors, of which, fusion to the FLI-1 gene occurs in about 90% of cases (1) . For this reason, these tumors are now more broadly known as the Ewing Sarcoma Family of Tumors (ESFTs).
ESFTs are among the most aggressive tumors encountered in children and young adults, both morphologically and clinically. They require equally aggressive therapy, including surgery or radiation of the primary tumor site, and intensive multi-agent chemotherapy (2) . Presently, ~70% of Ewing Sarcoma patients with localized disease (3) , and just 20-30% of patients with metastatic disease (4), survive for 5 years after initial diagnosis; additional therapeutic options are badly needed.
Tumor recurrence is a serious problem following ESFT therapy, and 30-40% of Ewing Sarcoma patients with localized tumors develop recurrent disease (5) . Such patients have a 5-year survival rate of just 13% (6) . The addition of adjunctive, immune-activating, therapies delivered during the first remission has the potential to reduce recurrence rates (7), both through the capacity of the immune system to mop up residual disease, and through the stimulation of immune "memory". The junction region where the EWS and FLI-1 genes fuse, also known as the breakpoint, confers a region of novelty in the EWS-FLI-1 protein, and therefore provides a means to target selectively the immune system to EWS-FLI-1 In this study we investigated the capacity of peptides derived from EWS-FLI-1 Type 1, presented on a common HLA-type, HLA-A2.1, to activate CTL capable of recognizing and killing ESFT carrying the EWS-FLI-1 Type 1 translocation. Anticipating that native peptides would be poorly immunogenic (10), we also studied the immune-stimulating properties of native peptides modified at key binding residues in order to improve the binding affinity for HLA-A2.1.
We show that EWS-FLI-1 Type 1-derived peptides have a poor capacity to activate CTL, resulting in weak CTL killing of ESFT cells. The modification of key binding residues, in contrast, results in potent CTL activation, strong CTL killing across a range of ESFT types and increased survival of mice with established Ewing Sarcoma xenografts. Author Manuscript Published OnlineFirst on August 9, 2012; DOI: 10.1158/1078-0432.CCR- Anti-HLA-A2.1 mAb (BB7.2), and anti-CD8 (53-6.7) were purchased from BD biosciences.
MATERIALS AND METHODS

Mice
Anti-CD40 (3/23) was from Serotec (Oxford, UK). PE-HLA-A2.1/YLNPSVDSV, and PE-HLA-A2.1/GILGFVFTL MHC Pentamers were from ProImmune (Oxford, UK). All peptides were synthesized by Thinkpeptides (ProImmune Ltd). Modified peptide sequences were compared against a human protein sequence database (http://web.expasy.org/blast/) performed at the Swiss Institute of Bioinformatics using the BLAST network service and the NCBI BLAST 2 software; no homology to human proteins was observed.
Cell lines
TC-71 and TC-32 cells were a kind gift from Dr. Aykut Üren, Georgetown University Medical Center, Washington, D.C (12) . Rh1 (EW8) cells were a kind gift from Dr. Peter Houghton, Nationwide Children's Hospital, Columbus, Ohio (13) . TC-174 and TTC-547 were a kind gift from Prof. Timothy Triche, University of Southern California, Los Angeles, CA (14) . T2, SK-PN-DW and SK-ES-1 were from the ATCC, initially authenticated by STR profiling, and passaged for less than 6 months following resuscitation. A673 and EWS502 were provided by S.L., and WE-68, SK-N-MC, STA-ET-1, and TC-83 by F.V.V. RD-ES was a kind gift from Dr.
Lee Helman, National Cancer Institute, Bethesda, MD.
Screening of ESFT cell lines
HLA-A2.1 expression was determined by FACS. Cells with low or undetectable HLA-A2.1 expression were cultured for 48 hours in the presence of 300U/ml rhIFN-γ (R&D Systems) to increase surface MHC expression, and re-analysed. The presence of the EWS-FLI-1 type 1 translocations was determined by RT-PCR as described (15) .
Target peptide prediction
The online "SYFPEITHI" database (http://www.syfpeithi.de/) was used to predict HLA-A2 Author Manuscript Published OnlineFirst on August 9, 2012; DOI: 10.1158/1078-0432.CCR- cells using a FACSCanto II Analyzer as described (17) . An irrelevant peptide, GILGFVFTL (Influenza A matrix peptide 58-66), was used to determine non-specific CTL killing, which was subtracted from all subsequent test data.
In vitro generation of Human CTL
Characterized, cryopreserved human PBMC were purchased from Cellular Technology Ltd (Cleveland, OH, USA). HLA-A2 + donors were selected based on known recall reactivity to Influenza A peptides. PBMC were cultured for 4 weeks to generate CTL according to an established protocol (18) . To assess CTL activity, PBMC were cultured with CFSE-labeled TC-71 cells as above at a ratio of 20:1.
Creation of TC-71-Luc
A lentiviral vector encoding both green fluorescent protein and firefly luciferase was used for the transduction of TC-71 cells. The vector was generated using a third generation packaging system (19), co-transfecting 293T cells (System Biosciences) with the lentiviral expression CD8 T-cells derived, cultured, and negatively selected as described in CTL killing assays above were adoptively transferred i.v. Tumor growth was monitored by bioluminescence imaging. Blind assessments of animal health were performed.
Bioluminescence Imaging
The Xenogen IVIS-50™ Bioluminescence Imaging System was used to assess tumor growth.
SCID/beige mice were anesthetized with isoflurane and injected i.p. with 150 mg/kg of Dluciferin (Caliper LifeSciences) in PBS. Ten minutes after injection, and under continued isoflurane inhalation, the mice were imaged for a period of 5 minutes. Using Living Image® software (Xenogen), the luminescence signal was represented as a heat map superimposed over a grayscale photograph of the animal.
MRI Imaging
Mouse tumor images were acquired on an ASPECT Model M2 1T tabletop MRI scanner (ASPECT Magnet Technologies Ltd., Netanya, Israel). VivoQuant (inviCRO, Boston MA) software was used to visualize DICOM datasets.
Statistical analysis
Statistical comparisons of mean values were performed using unpaired Student's t-test.
Statistical comparisons of survival curves were performed using the logrank test with the null hypothesis that treatments did not change survival. P < 0.05 (*) was considered significant. P < 0.005 (**) and P < 0.001 (***) are indicated. 
RESULTS
Identification of EWS-FLI-1 Type 1 target peptides
The affinity with which peptides bind to MHC Class-I is critical for the induction of CTL activation. Therefore, we used the SYFPEITHI and BIMAS databases to predict the binding affinity of native peptide sequences that span the breakpoint region of EWS-FLI-1 type 1 to HLA-A2.1. For each peptide that spans the fusion region between EWS and FLI-1, a relatively low affinity score was predicted (Table 1) . Of these, highest SYFPEITHI score, 15, was predicted for QQNPSYDSV.
The low predicted binding scores for these peptides suggested that these sequences would not bind with the affinity required to induce CTL activation, and would therefore not be suitable for use in targeting CTL responses against cells carrying the EWS-FLI-1 Type 1 translocation.
However, appropriately modified tumor peptides can often prime the immune response to act against native tumor peptides incapable of inducing an immune response on their own (21) . We therefore substituted key anchor residues in 3 native peptides with the most promising SYFPEITHI affinity scores: SYGQQNPSY (score = 5), SSYGQQNPS (score = 6), and QQNPSYDSV (score =15), according to previously described HLA-A2.1-binding principles (22) . As expected, the predicted binding affinities of peptides modified in this manner increased substantially both SYFPEITHI and BIMAS scores following the substitution of residues at positions 1, 2, 6, and/or 9 with Tyrosine (Y), Leucine (L), Isoleucine (I) and/or Valine (V: see Table 2 ). Author Manuscript Published OnlineFirst on August 9, 2012; DOI: 10.1158/1078-0432.CCR- HLA-A2.1. Binding to HLA-A2.1 was detected using the REVEAL MHC-Peptide Binding Assay; an antibody staining assay based on the conformational changes that only occur when peptide, MHC class I, and β2m form a complex. As shown in Figure 1 (A-C) , most of the modified peptides, but not all, displayed a stronger binding capacity than the corresponding native peptides from which they were derived. Together, these data show that the HLA-A2.1-binding of native EWS-FLI-1 Type 1 junction peptides can be improved through the modification of anchor residues.
Peptide modification increases stabilization of HLA-A2.1 molecules on the cell surface
We also sought to determine whether modified peptides would show an improved capacity to stabilize MHC molecules on the live cell surface, as the ability of peptide/MHC complexes to remain on the cell surface is critical to the initiation of T-cell activation. We selected modified peptides with a predicted SYFPEITHI score greater than 21 and improved binding to HLA-A2.1 for further study. Human T2 cells express HLA-A2.1 but lack Transporters associated with Antigen Processing (TAP); consequently their cell surface MHC molecules are empty. The association of exogenously added peptides with the empty HLA-A2.1 molecules stabilizes them and results in increased levels of cell surface HLA-A2.1 molecules, recognizable by monoclonal antibodies and flow cytometry. Unlike the native peptide sequences SYGQQNPSY (#1) and SSYGQQNPS (#9) from which they were derived, each of the modified peptides (#4, #6, #8, and #11, #12, and #13 respectively) showed improved stabilization of cell surface MHC (Fig. 1D-E) . The native sequence QQNPSYDSV (#14) was found to stabilize cell surface MHC molecules at a high concentration (50µg/ml), but not at low concentrations <10µg/ml (Fig. 1F) . Two of the modified QQNPSYDSV peptides (#18 and #22) did not show 
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remaining four peptides (#20, #21, #23, and #24) revealed an excellent capacity for MHC stabilization, even at a 50-fold reduction in peptide concentration (1µg/ml). One peptide in particular, YLNPSVDSV (#24), was found to stabilize MHC to a similar extent as 50µg/ml of the native peptide QQNPSYDSV (#14) at a 500-fold lower peptide concentration (0.1µg/ml).
These data show that modifying native EWS-FLI-1 Type 1 junction peptides can result in better retention of peptide/MHC complexes on the cell surface.
CTL raised against modified peptides display improved killing of Ewing Sarcoma cells
A critical question when modifying tumor peptides to induce CTL activation is whether or not CTL raised against the modified peptide will recognize and kill tumor cells expressing the native peptide. We conducted CTL assays using purified CD8 T-cells derived from HLA- Figure 1G , the native peptide SYGQQNPSY (#1) was not able to induce a detectable CTL response, and the CTL responses induced by the three modified SYGQQNPSY peptides (#4, #6, and #8) were weak (≤15% killing). The native peptide SSYGQQNPS (#9) also induced weak CTL activity (<10%: Fig.   1 .H), although each of the three modified SSYGQQNPS peptides (#11, #12, and #13) induced an appreciable increase in CTL activity, with up to ~25% killing. Interestingly, these 3 peptides all induced strong CD8 T-cell proliferation during in vitro restimulation (data not shown). However this did not appear to correlate with a high level of target cell killing. Of the native peptides, QQNPSYDSV (#14) induced the strongest CTL response with ~15-18% killing ( Fig. 1.I) . 14 Surprisingly, its modified derivative, YLNPSYDSV (#20), did not induce CTL killing despite displaying an increased capacity to stabilize cell-surface MHC (see Fig 1.F) . The strongest CTL activity was displayed by modified peptides QINPSVDSV (#21) and YLNPSVDSV (#24) which both displayed over 40% killing. Peptide YLNPSVDSV (#24) was found to be considerably more immunogenic than native peptide QQNPSYDSV (#14), as evidenced by the consistently increased size of draining lymph nodes following vaccination (Supplementary Fig. S1 ).
Collectively, these data show that the CTL-inducing capacity of native EWS-FLI-1 Type 1 junction peptides presented on HLA-A2.1 is low, but modification of key MHC-binding anchor residues can result in the activation of CTL clones capable of recognizing and killing unmodified tumor cells expressing native EWS-FLI-1 Type 1 junction peptides. Due to its consistent ability to induce strong immune activation, peptide YLNPSVDSV (#24) was selected for further studies.
Adoptive immunotherapy with EWS-FLI-1 Type 1 -targeting CTL results in enhanced survival of tumor-bearing mice
The TC-71 Ewing sarcoma cell line is known to be tumorigenic in SCID/beige mice (12), and has been used for preclinical in vivo studies for Ewing Sarcoma (12, 24) . Author Manuscript Published OnlineFirst on August 9, 2012; DOI: 10.1158/1078-0432.CCR- YLNPSVDSV significantly increased mouse survival time when compared with untreated mice or mice receiving T-cells recognizing an irrelevant peptide (Flu: GILGFVFTL) (Fig. 2B , P < 0.05). Ovaries and kidneys/adrenals were a strong metastatic site for these tumors (Fig. 2C) . 
EWS-FLI-1 Type 1 -targeting CTL kill multiple members of the Ewing Sarcoma Family of Tumors
The ESFTs are grouped together because they share expression of fusion genes like the EWS-FLI-1 translocation. We therefore asked whether multiple ESFT members would be susceptible 
Stimulation of PBMCs from healthy human donors with modified EWS-FLI-1 Type 1 peptide induces T-cell expansion and potent EWS-FLI-1 Type 1-targeted CTL Activity.
Since our results suggested that YLNPSVDSV (#24) peptide could induce EWS-FLI-1- assessed through CD8 and MHC pentamer co-staining. Due to the low binding affinity of the native peptide to HLA-A2.1 we were unable to make HLA-A2.1/QQNPSYDSV pentamer.
As shown in Fig. 3B , the baseline level of YLNPSVDSV-specific CD8 T-cells in unstimulated PBMC was low (~0.4%) compared with GILGFVFTL peptide (~0.5-1.4%); this is expected, due to the prior exposure of these patients to Influenza A. After 4 weeks of peptide stimulation, however, the level of CD8 T-cells specific for YLNPSVDSV peptide expanded to between 2.57% and 2.86%. We further examined the cytotoxic activity of these CTLs against TC-71 cells. As shown in Figure 3C , for each of the 3 donors tested YLNPSVDSV-specific CTL displayed substantially improved killing of TC-71 Ewing sarcoma cells compared to QQNPSYDSV-specific CTL. We also saw killing of TC-71 cells using YLNPSVDSV-specific CTL derived from a further 2 healthy donors, although comparative native-peptide specific CTL assays were not performed due to lack of expansion of these cells in culture (data not shown).
These results identify CD8 T-cells capable of recognizing a modified (YLNPSVDSV #24)
peptide from the junction region of the EWS-FLI-1 Type 1 translocation in the peripheral blood of healthy donors, and show that they can be readily activated by peptide, to kill efficiently cells bearing the EWS-FLI-1 Type 1 translocation.
DISCUSSION
The EWS-FLI-1 oncogene is well recognized as a highly promising therapeutic target for ESFT (26) . The complete lack of EWS-FLI-1 expression in healthy cells, coupled with the absolute requirement of diseased cells to maintain expression of this gene (27, 28) , have led to the development of several EWS-FLI-1-targeting therapies in recent years. While many of these studies have concentrated on disrupting the function of this oncogene (29, 30) , studies are also being conducted which attempt to activate the immune system specifically to target cells carrying EWS-FLI-1.
In a pilot clinical trial conducted by Dagher and colleagues (31), EWS-FLI-1-targeted immunotherapy was investigated using native junction peptides. In this study, patient peripheral blood leukocytes (PBL) were pulsed with long (15-18aa) peptides spanning the breakpoint region for both EWS-FLI-1 Type 1 and Type 2, irradiated, and injected intravenously into patients, who were then put on IL-2 therapy. No patients showed any evidence of peptidespecific cytokine release, and all patients suffered toxicity as a result of IL-2 therapy. However, this study was primarily a safety study incorporating immune compromised patients with bulky, rapidly progressing tumors. Importantly, no evidence of peptide-induced toxicity was found.
A subsequent study by the same group (7) 
